Entekave's nine-year market has increased 40-fold as local companies are pompishing

As the largest terminal for drug sales, hospitals guide the structure and direction of drug use, increasing by 6.6% in 2015 over the same period last year. In terms of the environment, growth across the pharmaceutical industry has slowed, with double-digit growth for more than a decade falling below 10% for the first time in 2015. The overall growth of drug purchases in sample hospitals slowed due to various factors such as drug price reduction, medical insurance charges, increased costs and the pharmaceutical environment.2,300 drugs were
included in sample hospital drug use statistics in 2015, according to the U.S. Department of Medicine. The top 100 drugs purchased accounted for 50.8% of the total amount, the top 50 drugs accounted for 33.9%, the top 30 drugs accounted for 24.1%, the top 20 drugs accounted for 18.1%, the top 10 drugs accounted for 10.7%.
the top 10 products for sample hospital medications in 2015 were: human haemoglobin, sodium chloride, neuroglycosides, clopidogrel, creatine phosphate, yew alcohol, entikave, prostyl, atovastatin, and lansolaquine. The top 10 products are more than 1.3 billion yuan, of which human haemoglobin has more than 2 billion yuan. It's worth noting that Entikave was in the top 10 for the first time in sample hospitals, and thymus pentagonides have fallen off the TOP10 list.
Among the top 10 products, there were 3 drugs for blood and hema production systems, namely, 2.02 billion yuan for human haemoglobin, 1.95 billion yuan for sodium chloride and 1.74 billion yuan for clopidogre, respectively, with a growth rate of 13.3. 8%, 2.5% and 8.8%; 3 cardiovascular system drugs, phosphate creatine medication amounted to 1.50 billion yuan, forefront of drug use amounted to 1.46 billion yuan, Atovastatin drug amounted to 1.44 billion yuan, growth rate 9.5%, 1.3% and 4.6%, respectively; The growth rate was 6.9%, the amount of anti-infective drugs was 1,470 million yuan, a growth rate of 21.6%, and the amount of drugs used in the digestive system was 1,350 million yuan, a growth rate of 0.6%.
top 10 products, the two most eye-catching products in 2015 were human haemoglobin and entincave, up more than 10% from a year earlier.to maintain high growth
According to statistics, there are 90 million hepatitis B virus carriers in China, of whom 28 million are chronic hepatitis B patients, the urgent need for treatment of about 7 million people. According to global sales data for nucleoside antiviral drugs in recent years, global sales of Entecave, Tenovwe, Ramifedin and Adelfowe exceeded $3.2 billion in 2014, of which Entecawe sales amounted to $1.74 billion, or 54.2%. Enticave accounts for more than half of the market share of nucleoside antiviral drugs and has become the world's leading product of nucleoside antiviral drugs. In recent years, Enticave has maintained high growth and is the fastest growing variety of key nucleoside antiviral drugs. Several other products, in addition to The Nofowe to maintain a relatively fast growth rate, Ramifeding, Adelforwe has shown a downward trend.
According to domestic sample hospital data, in 2015, Entikawe, Adelfowe, Tybived, Ramifedin and Tenove sample hospitals had sales of 2.32 billion yuan, of which Entikawe sales were 1.47 billion yuan, or 63.4%; Wei's sales amounted to 310 million yuan, or 13.2%, to 280 million yuan, or 12.3%, to 230 million yuan, Tonofowe's sales to 230 million yuan, or 10.1%, and to Nofowe's 25.09 million yuan, or 1.1%. Entikawe accounts for more than 60% of the domestic market.
from the 2006-2015 domestic sample hospital sales trends, in 2006, Entikaway sales of 36.15 million yuan, sales in 2015 of 1.47 billion yuan, 9 years of market growth of 40.6 times. The compound growth rate from 2006 to 2015 was 50.9%, with outstanding performance in the domestic nucleoside antiviral drug market. After Enticave's listing, due to its good efficacy and academic drive of various enterprises, the market sales grew rapidly and has become the leading heavy-weight products in the anti-HBV drug market.National enterprises are ready to develop
Entekawe is a newer anti-hepatitis B virus nucleotide drugs developed by Shishi Shiguibao, in March 2005 the U.S. FDA approved Entecawe with the commodity name "Baraclude" listed, belongs to the current antiviral capacity of the strongest, the lowest rate of mutation of low resistance drugs. In November 2005, Shanghai Shiguibao's Entikawe obtained production approval, the commodity named "Boluding". Since the product entered the Chinese market, it has rapidly replaced the early nucleoside drug Adelfovir in 2009 and has been ranked No. 1. At present, a total of 10 domestic enterprises to participate in the competition, involving dosage forms of ordinary tablets, capsules and dispersed tablets.
After searching the CFDA website, in 2010, Hainan Zhong and Pharmaceuticals Entekave capsules (commodity name: and Ding) and Jiangsu Zhengda Tianqing Pharmaceuticals Entekave dispersal tablets (commodity name: Run crowd) two domestic pharmaceutical companies have obtained production approval. In 2012, Jiangsu Zhengda Tianqing Pharmaceuticals' Entekave capsules and Malay acid Entekave tablets were also successfully listed. Zhengda Tianqing Pharmaceuticals has Entikave dispersion tablets, capsules and Malay acid Entekave tablets 3 dosage forms, the advantages are obvious.
according to domestic sample hospital data, Entikawe went through two stages: the market was in a relatively warm phase in 2006-2010 and the rapid growth stage in 2011-2015. Sales in 2006 were 36.15 million yuan, in 2010 300 million yuan, in 2015 the market size has reached 1.47 billion yuan, the market is leaping development.
Before 2010, only a hundred-time Meishi Guibao exclusive market, from 2010 onwards, domestic enterprises have broken the monopoly pattern, and since then a number of domestic enterprises Entikaway imitations have been approved, especially in recent years, the domestic market growth situation can be described as rapid, competition is extremely fierce.
In 2015, 10 enterprises in the Entekawe market have joined the competition, and the top 5 enterprises in sales are: Shanghai Shiguibao, Zhengda Tianqing Pharmaceuticals, Suzhou Dongrui Pharmaceuticals, Jiangxi Qingfeng Pharmaceuticals, Fujian Guangshengtang Pharmaceuticals, with sales of 840 million yuan, 460 million yuan, 68.44 million yuan, 43.11 million yuan and 42.93 million yuan, respectively. Among them, The "Boluding" market share of Shanghai Shiguibao in China and the United States is 57.4%, Zhengtianqing Pharmaceuticals' "Run People" "Tianding" accounts for 31.5%, Suzhou Dongrui Pharmaceutical products account for 4.7%, and other enterprises account for 6.5%. In terms of sales in 2015, Shanghai Shiguibao had the largest share, but grew by only 8.0% over the same period, while Zhengda Tianqing Pharmaceuticals accounted for more than 30%, up 48.1% from the same period. It can be seen that the positive day clear pharmaceutical industry is accelerating forward.
's future market development should not be underestimated. At present, the domestic declaration of Enticave preparations have more than 80 enterprises, can be described as unusually hot. It is worth noting that, in addition to the listed dosage forms, the new dosage forms being declared in China are Entekave particles, Entekave oral solution (children's type), Entekave oral disintegration tablets and Entekave oral solution film, the development of these new dosage forms will bring new impetus to future market growth. (Medical Economics)